Oramed Letter to Shareholders

Oramed-HTIT Joint Venture Update Nadav Kidron Chief Executive Officer Stock Repurchase Program Scilex Senior Secured Note Phase 3 Oral Insulin Trial in US JV with Chinese Partner, HTIT NEW YORK, June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. Dear Shareholder ...